News
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Novartis Ag (NYSE: NVS)Q2 2023 Earnings CallJul 18, 2023, 8:00 a.m. ET
Operator
Source Fool.com
AEVIS VICTORIA SA – Visana Beteiligungen AG becomes a shareholder of Swiss Medical Network SA
Why Novartis Stock Slipped on Friday
Pharmaceutical companies depend on the patent protection they receive for their goods, so it's never a good day when it is stripped away. That was the misfortune suffered by global pharmaceutical
AEVIS VICTORIA SA – Fabrice Zumbrunnen joins the Board of Directors of Swiss Medical Network SA
Why Shares of Vera Therapeutics Jumped Tuesday
Shares of Vera Therapeutics (NASDAQ: VERA) closed 16.9% higher on Tuesday after jumping as much as 23.5%. The clinical-stage biotech company announced positive news regarding trial results for one
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to
Why Shares of Chinook Therapeutics Skyrocketed On Monday
Shares of Chinook Therapeutics (NASDAQ: KDNY) were up more than 57% early Monday afternoon after the healthcare company agreed to a $3.2 billion buyout offer from Novartis.
Chinook is a
Is Novartis a Good Stock to Buy Right Now?
Novartis (NYSE: NVS) is a company in transition. Over the past several years, the Swiss multinational pharma giant has been busy divesting key assets such as its eye care unit Alcon, trimming costs
Why Analog Devices Stock Was Down This Week
Analog Devices (NASDAQ: ADI) shareholders lost ground to the market this week. The stock dropped 10% through Thursday trading, according to data provided by S&P Global Market Intelligence. That's
AEVIS VICTORIA SA – Increased revenues for the operational divisions, positive outlook for the current fiscal year. Organic growth of 9.2% in the first quarter 2023.
Why Shares of Rain Oncology Are Plummeting Today
Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders: all proposals approved
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders on 9 May 2023
AEVIS VICTORIA SA – Publication of the Annual Report 2022
AEVIS VICTORIA SA – Consolidated EBITDA 2022 up by more than 60% to between CHF 125 and 130 million (2021: CHF 78.4m); net profit 2022 will exceed CHF 60 million (2021: CHF 4.6m)
AEVIS VICTORIA SA – AEVIS VICTORIA achieved consolidated revenues of CHF 1.143bn in 2022, up 27.8% (CHF 895.0m) from prior year.
AEVIS VICTORIA SA – AEVS.SW – Nine-month revenues up 35.5% to CHF 831.0 million
AEVIS VICTORIA SA – AEVS.SW – Visana enters into the share capital of Hôpital du Jura Bernois, a subsidiary of Swiss Medical Network
AEVIS VICTORIA SA – AEVS.SW – Repayment of the CHF 145 million bond issued on 17 October 2016
AEVIS VICTORIA SA – AEVS.SW – Half-year results 2022: Net profit jumps to CHF 47.2 million
AEVIS VICTORIA SA – AEVS.SW: Revenues up by 42.6% to CHF 584.2 million (2021: CHF 409.8 million) in the first semester of 2022
AEVIS VICTORIA SA takes a stake in the Well digital health platform
AEVIS VICTORIA SA – First quarter 2022 consolidated revenue up by 61.6% to CHF 316.3 million
AEVIS VICTORIA SA: New revolving credit facility of CHF 250 million for Swiss Medical Network SA
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders: all proposals approved